Description
The 8F10 monoclonal antibody specifically recognizes CD267 which is also known as transmembrane activator and calcium-modulating and cyclophilin ligand interactor(transmembrane activator and CAML interactor or TACI). CD267 is encoded by Tnfrsf13b (tumor necrosis factor receptor superfamily member 13B). CD267 is a type III transmembrane protein receptor that binds to the ligands BAFF (BLyS), and APRIL. BAFF overproduction is associated with lupus erythematosus and Sjögren's disease, two systemic autoimmune diseases. CD267 is expressed most notably on maturing subsets of splenic B cells such as transition type 2 (T2) and marginal zone (MZ) B cells and also in activated T-cells. In CD267 deficient mice, B cell numbers are increased and mice develop autoimmune disorders suggesting that CD267 plays a role in B cell regulation.
Put all BD® AbSeq Reagents to be pooled into a Latch Rack for 500 µL Tubes (Thermo Fisher Scientific Cat. No. 4900). Arrange the tubes so that they can be easily uncapped and re-capped with an 8-Channel Screw Cap Tube Capper (Thermo Fisher Scientific Cat. No. 4105MAT) and the reagents aliquoted with a multi-channel pipette. BD® AbSeq tubes should be centrifuged for ≥ 30 seconds at 400 × g to ensure removal of any content in the cap/tube threads prior to the first opening.
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography and conjugated to BD® AbSeq oligonucleotide under optimal conditions.
1. This reagent has been pre-diluted for use at the recommended volume per test. Typical use is 2 µl for 1 × 10^6 cells in a 200-µl staining reaction.
2. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
4. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
5. Illumina is a trademark of Illumina, Inc.
6. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
7. Please refer to bd.com/genomics-resources for technical protocols.
8. For U.S. patents that may apply, see bd.com/patents.
